A Phase II, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine Followed by Recombinant, Multiclade HIV-1 Adenoviral Vector Vaccine in Healthy Adult Volunteers at Risk for HIV Infection
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- HIV Infections
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Primary Endpoint
- Safety and tolerability, as assessed by local and systemic reactogenicity signs and symptoms, laboratory measures of safety, and adverse and serious adverse events
- Status
- Withdrawn
- Last Updated
- 4 years ago
Overview
Brief Summary
The purpose of this study is to evaluate the safety and tolerability of and immune response to an HIV DNA vaccine followed by an adenoviral vector HIV vaccine in healthy African adults at risk for HIV infection.
Detailed Description
Due to the availability of antiretroviral therapy, AIDS-related deaths have lessened in the United States. However, these therapies are widely inaccessible to the developing world. The need for a safe and affordable vaccine that will prevent HIV infection is of utmost importance. To generate a broadly protective vaccine, it is necessary to develop a multivalent vaccine containing a defined combination of immunogens from the most globally prevalent HIV subtypes. This study will evaluate the safety, tolerability, and immunogenicity of a multiclade HIV-1 DNA plasmid vaccine,VRC-HIVDNA016-00-VP, followed by a multiclade recombinant HIV-1 adenoviral vector vaccine, HIVADV014-00-VP. This study will last about 27 months. Participants will be randomly assigned to one of two groups. Group A will receive the DNA vaccine at baseline, Month 1, and Month 2, and the adenoviral vector vaccine at Month 6; Group B will receive placebo. There will be 20 study visits over 2 years. Physical exams, vital signs measurements, adverse event evaluation, and medical and medication history will occur at each visit. HIV testing and counseling and blood and urine collection will occur at selected visits.
Investigators
Eligibility Criteria
Inclusion Criteria
- •At risk for HIV
- •Have had sexual intercourse with an HIV infected partner OR have had sexual intercourse with more than one person within the 3 months prior to study entry OR infected with a sexually transmitted disease within the 3 months prior to study entry
- •Willing to comply with the protocol
- •Willing to undergo HIV testing and HIV counseling and receive HIV test results
- •Willing to use acceptable forms of contraception
Exclusion Criteria
- •HIV-1 or HIV-2 infected
- •History of immunodeficiency or autoimmune disease
- •Use of corticosteroids or immunosuppressive, antiviral, anticancer, or other medications considered significant by investigator within 6 months prior to study entry
- •Certain abnormal laboratory values
- •Acute or chronic medical condition considered progressive
- •Hepatitis B or hepatitis C virus infection or untreated syphilis
- •Live attenuated vaccine within 30 days prior to study
- •Planned receipt of investigational product within 30 days after first vaccination
- •Other medically indicated subunit or killed vaccine within 14 days prior to study entry
- •Planned receipt of other medically killed vaccine investigational product within 14 days after first vaccination
Outcomes
Primary Outcomes
Safety and tolerability, as assessed by local and systemic reactogenicity signs and symptoms, laboratory measures of safety, and adverse and serious adverse events
Time Frame: throughout study
immunogenicity as assessed by the proportion of participants who develop HIV-specific T-cell responses and/or to ENV A-, B-, or C-specific antibodies and magnitude of those responses
Time Frame: throughout study
Secondary Outcomes
- Recruitment, enrollment, and retention rates by gender and risk category for participating trial sites(throughout study)
- safety, tolerability, and immunogenicity endpoints in participants with varying pre-existing immunity to adenovirus(throughout study)